Aurentz Vincent, Chief Business Officer at EPIRUS Biopharmaceuticals, Inc. (EPRS), bought 2,800 shares at $3.85 ($11K) on 2015-12-09, disclosed to the SEC on 2015-12-11.
Open-market purchase of $11k EPRS by Chief Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.